Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.
Donal McLornan, MBBCh, MRCP, PhD, FRCPath
Advertisement
Donal McLornan, MBBCh, MRCP, PhD, FRCPath, is a consultant, Hematology and Stem Cell Transplantation, University College London Hospitals NHS Foundation Trust.
Articles by Donal McLornan, MBBCh, MRCP, PhD, FRCPath
Donal McLornan, MBBCh, MRCP, PhD, FRCPath, discusses future research directions for an EBMT machine learning model for identifying and stratifying transplant risk in myelofibrosis.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC
2
Oral Administration Afforded by CDK2 Inhibitors May Ease the Price of Admission in Platinum-Resistant Ovarian Cancer
3
Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026
4
A global, randomized, double-blinded, Phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): updated efficacy and safety
5